AbbVie stays bullish on future performance as Skyrizi continues to impress — but 'price controls' would be a game changer - Endpoints News
7/29/2022 12:00:00 AM3 years 7 months ago
by John Carroll
by John Carroll
AbbVie’s executive team stayed right on track in Q2, with its Skyrizi franchise — now newly approved for Crohn’s — continuing to rack up impressive sales, making up for some unexpected weakness from a stronger dollar. The erosion of the Imbruvica franchise, h…
Most pharma TV commercials include a link at the end of the ad, offering a website link for viewers who want more information. It turns out millions of them do. So far in 2022, AbbVie, Novo Nordisk a… [+606 chars]
full article...